• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)

$3,500.00 – $7,000.00

Clear
SKU: KLI2065254 Category: Pharmaceuticals Market Research Pages: 180
  • Description
  • Table of Contents
  • Latest reports

Description

A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections).

Marketing planners in the pharmaceutical or diagnostic industries should have an understanding of the market impact of nosocomial infections, as it will be an important consideration in these markets into the near future.

This report. Hospital Acquired Infections (Nosocomial) : Diagnostic and Pharmaceutical Market Considerations : MRSA, HAP, Cdiff and Other market impact of treating the following infections are discussed in detail:

  • Acinetobacter baumannii
  • Clostridium difficile
  • Gastroenteritis
  • Hospital-acquired pneumonia (HAP) and ventilator associated pneumonia
  • Methicillin resistant staphylococcus aureus MRSA
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Stenotrophomonas maltophilia
  • Tuberculosis
  • Urinary tract infection
  • Vancomycin-resistant enterococcusThis report covers nosocomial infection diagnosis and therapeutics in a broad sense. It does not go into the detail of the dynamics of individual products in the marketplace. It discusses, however, the status of the field of nosocomial infection diagnostics and therapeutics, as a setting-specific field of application.

    The Most Recent and Relevant Epidemiological Statistics on HAIs

    There is no ‘noscomial infection’ market per se, it is reflected in sales and revenues of all infectious disease testing and therapeutics. Therefore Kalorama’s market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products).

    In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing needs.

    Estimates of Market Impact

    As mentioned above, the primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutics technologies that are currently available and attempt to project trends in these product areas.
    Company Profiles and Competitive Assessment

    This report examines the key players in HAI infection diagnostics and pharmaceutical treatement, their revenues, and activity in the market. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology. This presages opportunities for new competitors

    The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.

Table of Contents

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Specific Nosocomial Infections
  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Gastroenteritis
  • Hospital-Acquired Pneumonia (HAP)
  • Ventilator-Associated Pneumonia (VAP)
  • Pseudomonas Aeruginos
  • Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
  • Stenotrophomonas Maltophilia
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-Resistant Enterococcus
  • Scope and Methodolog
  • Market Considerations
  • Trends Affecting Nosocomial Infection Applications

CHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS

  • Overview
  • Specific Nosocomial Infections
    • Acinetobacter Baumannii
    • Clostridium Difficile
    • Gastroenteritis
    • Hospital-Acquired Pneumonia
      • Healthcare-Associated Pneumonia
      • Hospital-Acquired Pneumonia
      • Ventilator-Associated Pneumonia
    • Pseudomonas Aeruginosa
    • Staphylococcus Aureus
    • Stenotrophomonas maltophilia
    • Tuberculosis
    • Urinary Tract Infections

CHAPTER THREE: DRUG-RESISTANT NOSOCOMIAL INFECTIONS

  • Overview
  • Drug-Resistant Acinetobacter
  • Drug-Resistant C. Difficile
  • Drug-Resistant Enterococci
  • Drug-Resistant Pneumonia
  • Drug-Resistant Pseudomonas Aeruginosa
  • Drug-Resistant Staphylococcus Aureus
  • Drug-Resistant Tuberculosis
  • Drug-Resistance/Susceptibility Testing
  • Genotypic Methods
    • DNA Sequencing
    • Solid-phase Hybridization Techniques
    • Microarrays
    • Real-time Polymerase Chain Reaction Techniques
    • Phenotypic Method
    • Phage-based Assay
    • Colorimetric Method
    • The Nitrate Reductase Assay

CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS

  • Overview
    • Acinetobacter Baumannii
    • Clostridium Difficile
    • Enterococci
    • Drug-Resistant Pneumonia
    • Pseudomonas aeruginosa
    • Staphylococcus aureus
    • Drug Resistant Tuberculosis

CHAPTER FIVE: COMPANY SNAPSHOTS

  • Abbott Pharmaceuticals (Division of Abbott Laboratories)
  • AdvanDx, Inc.
  • Becton Dickinson and Company
  • Binax, Inc. (Division of Inverness Medical Innovations)
  • Cellestis
  • Cepheid
  • GeneOhm Sciences (Division of Becton Dickinson)
  • GlaxoSmithKline plc
  • Meridian Bioscience, Inc.
  • Merck & Co.
  • Schering-Plough
  • Techlab, Inc.
  • Trek Diagnostics Systems, Ltd. (A Subsidiary of Magellan Biosciences)
  • Volu Sol

CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS

  • First Conclusion
    • Implications
  • Second Conclusion
    • Implications
  • Third Conclusion
    • Implications
  • Fourth Conclusion
    • Implications
  • Fifth Conclusion
    • Implications
  • Sixth Conclusion
    • Implications
  • Seventh Conclusion
    • Implications

L I S T O F E X H I B I T S

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1
    • Frequency of the Most Common Nosocomial Infections
  • Table 1-2
    • Common Bacterial Nosocomial Infections

CHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS

  • Table 2-1
    • Frequency of the Most Common Nosocomial Infections
  • Table 2-2
    • Common Bacterial Nosocomial Infections

CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS

  • Table 4-1
    • Common Sites of A. baumannii Presence
  • Table 4-2
    • Global Susceptibility of A. baumannii to Selected Antibiotics (% Susceptibility)
  • Table 4-3
    • Meropenem resistance in A. baumannii (% of Isolates)
  • Figure 4-1
    • National Estimates of United States Short-Stay Hospital Discharges with Clostridium difficile Listed as Primary or as Any Diagnosis: 1996 – 2003
  • Table 4-4
    • Overall Rates of Any Listed Clostridium difficile Discharge Diagnosis by Various Demographic Factors: 1996 – 2003
  • Figure 4-2
    • Rates of United States Short-Stay Hospital Discharges with Clostridium difficile Listed as Any Diagnosis, by Age: 1996 – 2003
  • Figure 4-3
    • Rates of United States Short-Stay Hospital Discharges with Clostridium difficile Listed as Any Diagnosis by Region: 1996 – 2003
  • Figure 4-4
    • Proportion of United States Short-Stay Hospital Discharges with Clostridium difficile Listed as Any Diagnosis, by Hospital Size: 1996 – 2003 (Number of Beds)
  • Figure 4-5
    • States (40) with Significant Levels of the BI/NAP1/027 Strain of Clostridium difficile: 2008
  • Figure 4-6
    • Epidemiology of Enterococcal Infection Based Susceptibility Results Obtained by The Surveillance Network (TSN) Database-USA: 1995 – September 1, 1997
  • Figure 4-7
    • Vancomycin-Resistant Enterocci Among ICU Patients: 1995 – 2004
  • Table 4-5
    • The Most Common Multidrug Resistance Bacteria Associated with VAP
  • Figure 4-8
    • Third-Generation Cephalosproin-Resistant Klebsiella pneumoniae Among ICU Patients: 1995 – 2004
  • Figure 4-9
    • Fluoroquinolone-Resistant Pseudomonas Aeruginosa Among ICU Patients: 1995 – 2004
  • Figure 4-10
    • Methicillin (Oxacilllin)-Resistant Staphylococcus aureus (MRSA) Among ICU Patients: 1995 – 2004
  • Table 4-6
    • Most Recent Global TB Estimates: 2006

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    World Market for Anti-infectives Volume III: The World Market for Antiviral Medications, The

    $1,875.00 – $3,750.00
  • Placeholder image

    The Market for Lead Optimization Tools and Services: Applying the New “Omics” to Enhance Drug Discovery

    $1,875.00 – $3,750.00
  • Placeholder image

    Market for Generic Biologics: Issues, Trends, and Market Potential, The

    $1,500.00 – $3,000.00
  • Placeholder image

    Type II Diabetes: The 45 Market in the United States for Drugs and Diagnostics

    $2,995.00 – $5,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Kalorama Medical Device Bundle (Infusion Pumps, Reusable Devices, Minimally...Medical Beds and Medical Chairs
Scroll to top